SLOW ANAKINRA DESENSITISATION PROTOCOL DESIGN FOR DELAYED HYPERSENSIBILITY REACTION

/Salut Institut Català de la Salut

H. Suñer[1]; M. Martín Marqués[1]; O. Esteso Hontoria[2]; C. Badia Santolaria[2]; A. Sanjuán Belda[1]; I. Sacanella Anglés[1]; D. Pascual Carbonell[1]; S. Conde Giner[1]; C.J. Cortés Sánchez[1]; A. Garcia Molina[1]; L. Canadell Vilarrasa[1]

HJ23 Hospital Universitari Joan XXIII ICS Camp de Tarragona

[1] Pharmacy Department, Hospital Universitari Joan XXIII, Tarragona, Spain

[2] Allergology Department, Hospital Universitari Joan XXIII, Tarragona, Spain

Abstract Number: **3PC-008**

L04- IMMUNOSUPPRESSANTS

BACKGROUND



ANAKINRA is a recombinant human IL-1 receptor antagonist

Rheumatic arthritis(RA)

Nonetheless their administration has been associated with a severe delayed injection-site reaction without a fully understood pathogenesis.

To deal with **DESENSITISATION SCHEMES**

OBJECTIVES

The aim is to describe the design of a slow desensitisation protocol (SDP) for subcutaneous (SC) anakinra for patients who have failed the rapid desensitisation scheme (RDP).

MATERIALS AND METHODS

- RA
- Treated with **SC anakinra** after failing other lines
- Severe **injection-site reaction** after 3 weeks of treatment

RPD

SDP DESIGN

56 DOSES

[ ] Min. 0,1 mg — Max. 100 mg

Dose change was performed every 3-4 days

To prevent hypersensibility reactions:

ANTIHISTAMINES DURING THE SDP

Anakinra 100 mg/0,67 ml injection

Mother solution (MS): 100 mg anakinra + 0,33 mL physiological serum (SF)

0,5 mL from MS + 9,5 mL SF

1:10 — concentration 5 mg/ml — Doses preparation

1 mL from 1:10 + 4 mL SF

1:5 — concentration 1 mg/ml — Doses preparation

RESULTS

RAPID DESENSITISATION

SLOW DESENSITISATION

At first the lowest dose (0,1 mg) was not tolerated by the patient

It was decided to add antihistamines during the process

If any dose could react, the dose change was done instead of 3 after 5-7 days.

ACTUAL

The patient has completed the doses until 50 mg without adverse reactions.

CONCLUSION AND RELEVANCE

The **SDP** proposed by allergist in collaboration with hospital pharmacist has allowed the **safe administration** of anakinra, **avoiding a loss of the last therapeutic line** possible in a patient with RA.

eahp european association of hospital pharmacists

27th EAHP CONGRESS 22-23-24 MARCH 2023 Lisbon

helesubar@gmail.com

@helesubar